Innovating Works

filtrando por convocatoria: HORIZON-HLTH-2022-DISEASE-06-04-two-stage

NANEMIAR: Nanomedicine Approach to Normalize Erythrocyte Maturation in Congenital Anemia by messenger RNA FUNDACIÓN PARA LA FORMACIÓN E INVESTIGACIÓN SANITARIAS DE LA REGIÓN DE MURCIA tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Messenger RNA (mRNA) has recently proven itself as a prophylactic modality that can be rapidly developed and employed with high efficacy and...
2023-03-15 - 2026-09-30 | Financiado
BAXERNA 2.0: Immunopeptidomics based Development of Next Generation Bacterial mRNA Vaccines BAXERNA 2.0 will establish a new vaccine development pipeline based on dramatically improved immunopeptidomics screening and innovative mRNA...
2023-04-12 - 2028-06-30 | Financiado
TheRaCil: Therapies for Renal Ciliopathies Ciliopathies are a large group of rare and severe genetic diseases caused by dysfunction of the primary cilium, a microtubule-based cell sur...
2023-05-04 - 2027-06-30 | Financiado
SIMPATHIC: Accelerating drug repurposing for rare neurological neurometabolic and neuromuscular disorders by e... Drug repurposing can fill an important gap for rare disease patient groups with large unmet medical needs. In comparison to traditional drug...
2023-04-05 - 2028-06-30 | Financiado
RESTORE VISION: Novel advanced and repurposed therapeutics for vision restoration in a group of severe rare ocular s... Rare Eye Diseases (REDs) are a major cause of visual impairment and blindness in Europe, affecting patients of all ages. The RESTORE VISION...
2023-04-06 - 2027-04-30 | Financiado
NEXGEN-PD: Next Generation Vaccine Platform Leveraging Skin Immunity to Provide Disease Modifying Treatment of... Parkinson’s Disease (PD) is a major neurodegenerative disorder with no established treatment modalities capable of modifying disease patholo...
2023-03-15 - 2027-03-31 | Financiado
NOSEVAC: INNOVATIVE NASAL VACCINES TO PREVENT PATHOGEN COLONIZATION AND INFECTION IN THE UPPER RESPIRATORY TR... Bacterial and viral respiratory infections are a leading cause of morbidity and mortality worldwide. Streptococcus pneumoniae and Bordetella...
2023-04-21 - 2028-04-30 | Financiado
Vax2Muc: NEXT GENERATION VACCINES AGAINST GASTROINTESTINAL MUCOSAL PATHOGENS USING HELICOBACTER PYLORI AS MO... To overcome antimicrobial resistance (AMR) compromising global public health, novel strategies to develop next generation vaccines against A...
2023-04-14 - 2028-06-30 | Financiado
ITHEMYC: Novel immunotherapies for tuberculosis and other mycobacterial diseases Tuberculosis (TB) remains the leading cause of death due to a single pathogen, Mycobacterium tuberculosis (Mtb; except in 2020-2022, when it...
2023-05-05 - 2027-05-31 | Financiado
TBVAC-HORIZON: Improving understanding of lung immunity in tuberculosis to establish a diverse innovative TB vacci... Tuberculosis (TB) remains one of the most devastating infectious diseases worldwide, killing over 4,000 people every day. Prevention of tube...
2023-04-24 - 2027-03-31 | Financiado
CAPTIVATE: CorrelAtes of Protective immuniTy driven Investigation of malaria VAccine combinaTion stratEgies Malaria remains a serious health concern worldwide, with P. falciparum considered one of the deadliest human parasites. Yet, the currently a...
2023-10-09 - 2028-04-30 | Financiado
IN-ARMOR: THERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO EFFECTIVELY COMBAT ANTIMICROBIAL RESIS... Antimicrobial resistance (AMR) & multi-drug resistance, whereby pathogens evolve to resist antibiotic drugs, is designated by WHO one of the...
2023-03-15 - 2027-04-30 | Financiado
MAGIC: Next generation models and genetic therapies for rare neuromuscular diseases Muscular dystrophies are severe genetic disorders characterised by muscle wasting, impaired mobility and premature death, which to date rema...
2023-04-28 - 2027-05-31 | Financiado
LightCure: LightCure Light for double specificity and efficacy without burden Congenital hyperinsulinism (CHI) is a group of rare diseases of newborns and infants with functionally defective nonneoplastic beta-cells th...
2023-12-07 - 2029-12-31 | Financiado
TiilT: Preclinical development of a 3rd generation interleukin 2 targeted to inflammatory sites As major players in the regulation of immune responses, regulatory T cells (Tregs) are important therapeutic targets for autoimmune and infl...
2023-05-05 - 2028-05-31 | Financiado
FLUniversal: Intranasal rapid acting vaccine for all seasonal and pandemic influenza viruses "Researchers worldwide have been working to develop a universal flu vaccine, but no breakthrough has yet been achieved. FLUniversal is not "...
2023-05-08 - 2027-05-31 | Financiado